JOAQUIM BOSCH BARRERA

Projectes

Oncologia de Precisió de Girona

Estudi "Organ specific biomarkers and therapies to improve the management of brain metastasis".

Codi oficial: La Marató 201906-30 Data inici: 30/09/2020 Data fi: 31/01/2024 Investigador/a principal: JOAQUIM BOSCH BARRERA Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 109,562.50 €

Genètica Cardiovascular

Data-driven cancer genome interpretation for personalised cancer treatment

Codi oficial: 101057509 Data inici: 01/11/2022 Data fi: 31/10/2027 Investigador/a principal: JOAN BRUNET VIDAL, RAMON BRUGADA TERRADELLAS Organisme finançador: EUROPEAN COMISSION Ajuda: 218,975 €

Metabolisme i Càncer

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Metabolisme i càncer

Codi oficial: 2021 SGR 01507 Data inici: 01/01/2022 Data fi: 31/12/2024 Investigador/a principal: BEGOÑA MARTIN CASTILLO Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 24,000 €

Publicacions

Oncologia de Precisió de Girona

Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

SCIENTIFIC REPORTS, 2023, 13, 3620-3620 dx.doi.org/10.1038/s41598-023-30374-9

Oncologia de Precisió de Girona , Metabolisme i Càncer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Oncologia de Precisió de Girona

Janik A, Torrente M, Costabello L, Calvo V, Walsh B, Camps C, Mohamed SK, Ortega AL, Novácek V, Massutí B, Minervini P, Campelo MRG, Del Barco E, Bosch-Barrera J, Menasalvas E, Timilsina M, Provencio M

Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.

Jco Clinical Cancer Informatics, 2023, 7 dx.doi.org/10.1200/CCI.22.00062

Oncologia de Precisió de Girona

Provencio M, Nadal E, González-Larriba JL, Martínez-Martí A, Bernabé R, Bosch-Barrera J, Casal-Rubio J, Calvo V, Insa A, Ponce S, Reguart N, de Castro J, Mosquera J, Cobo M, Aguilar A, López Vivanco G, Camps C, López-Castro R, Morán T, Barneto I, Rodríguez-Abreu D, Serna-Blasco R, Benítez R, Aguado de la Rosa C, Palmero R, Hernando-Trancho F, Martín-López J, Cruz-Bermúdez A, Massuti B, Romero A

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389, 504-513 dx.doi.org/10.1056/NEJMoa2215530

Metabolisme i Càncer , Epidemiologia descriptiva, genètica i prevenció del càncer , Oncologia de Precisió de Girona

Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019

Metabolisme i Càncer , Oncologia de Precisió de Girona

Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N, RENACER, Valiente M

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8

Oncologia de Precisió de Girona

Provencio M, Cobo M, Rodriguez-Abreu D, Calvo V, Carcereny E, Cantero A, Bernabé R, Benitez G, Castro RL, Massutí B, Del Barco E, García Campelo R, Guirado M, Camps C, Ortega AL, González Larriba JL, Sánchez A, Casal J, Sala MA, Juan-Vidal O, Bosch-Barrera J, Oramas J, Dómine M, Trigo JM, Blanco R, Calzas J, Morilla I, Padilla A, Pimentao J, Sousa PA, Torrente M

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Bmc Cancer, 2022, 22, 732-732 dx.doi.org/10.1186/s12885-022-09830-8

Metabolisme i Càncer , Oncologia de Precisió de Girona

Verdura S, Encinar JA, Fernández-Arroyo S, Joven J, Cuyàs E, Bosch-Barrera J, Menendez JA

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 dx.doi.org/10.3390/ijms23179986

Oncologia de Precisió de Girona

Serna-Blasco R, Sánchez-Herrero E, Robado de Lope L, Sanz-Moreno S, Rodríguez-Festa A, Ares-Trotta D, Cruz-Bermúdez A, Franco F, Sánchez-Hernández A, Campayo MJ, García-Girón C, Dómine M, Blasco A, Sánchez JM, Oramas J, Bosch-Barrera J, Sala MÁ, Sereno M, Romero A, Provencio M

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation

Cancers, 2022, 14 dx.doi.org/10.3390/cancers14184446

Oncologia de Precisió de Girona

Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, Kristeleit R, Hiret S, Bajor DL, Cruz P, Beck JT, Ghosh S, Dabrowski C, Antony G, Duan T, Veneris J, Zografos E, Subramanian J

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.

CLINICAL LUNG CANCER, 2022, 23, 415-427 dx.doi.org/10.1016/j.cllc.2022.05.013

12 3 4 5 6 7 8

Propietat intel·lectual

Joaquim Bosch Barrera

MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS

Número de publicació: EP20170382891 Data de publicació: 2019-06-26

Directori

Projectes

Publicacions

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.

Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation

Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.

Propietat intel·lectual

MEANS FOR PREVENTING AND TREATING BRAIN METASTASIS

Formulari de contacte

Coneix l’IDIBGI!